Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rafael Robledo

Internal Medicine Hammond, LA Medical Doctor

NPI 1497965198 CMS profile 159123

42388 Pelican Professional Park, Hammond, LA 70403

Open in the dashboard

General payments

$7,352

258 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rafael Robledo of Hammond, LA is reported in the CMS Open Payments database as having received $7,352 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,478 36
2024 General $1,461 33
2023 General $1,457 33
2022 General $770 34
2021 General $1,109 59
2020 General $563 35
2019 General $514 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rafael Robledo
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rafael Robledo were reported at $1,478. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rafael Robledo Internal Medicine median Middle half National median
2019 $514 $159 $48–$570 $163
2020 $563 $119 $33–$402 $114
2021 $1,109 $135 $37–$521 $132
2022 $770 $141 $42–$496 $149
2023 $1,457 $149 $45–$519 $160
2024 $1,461 $154 $47–$537 $164
2025 $1,478 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,445 27 payments
  2. Amgen Inc. $696 22 payments
  3. Novo Nordisk Inc $438 18 payments
  4. AbbVie, Inc. $402 24 payments
  5. Janssen Pharmaceuticals, Inc $353 11 payments
  6. Abbott Laboratories $343 4 payments
  7. Teva Pharmaceuticals USA, Inc. $280 10 payments
  8. Pfizer Inc. $276 17 payments
  9. GlaxoSmithKline, LLC. $273 11 payments
  10. Neurocrine Biosciences, Inc. $260 3 payments
  11. Other $2,585 111 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,337 257 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $596 15 payments
  2. BREZTRI $537 6 payments
  3. Repatha $318 11 payments
  4. Ozempic $296 14 payments
  5. RYBELSUS $290 15 payments
  6. Austedo XR $280 10 payments
  7. AIRSUPRA $267 3 payments
  8. INGREZZA $260 3 payments
  9. SPRAVATO $239 3 payments
  10. EVENITY $199 7 payments
  11. Other $5,206 242 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 269 drugs

Part D claims

26,376

Median for Internal Medicine: 777

Drug cost

$1,828,787

Median for Internal Medicine: $73,373

Branded share of claims

24.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 703 $275,242
Ozempic Semaglutide Brand 134 $133,296
Farxiga Dapagliflozin Propanediol Brand 205 $96,808
Entresto Sacubitril/Valsartan Brand 173 $85,365
Mounjaro Tirzepatide Brand 56 $74,475
Jardiance Empagliflozin Brand 167 $73,276
Trulicity Dulaglutide Brand 69 $67,572
Xifaxan Rifaximin Brand 23 $62,948
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 15 $55,933
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 67 $52,488

The 10 drugs with the highest cost, of 269 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$301,760

Of which drugs: $8

Medicare patients

558

Average age 74

Services billed

4,323

309 women, 249 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 54%
Ischemic heart disease 50%
Depression 50%
Heart failure 46%
Chronic kidney disease 45%
Atrial fibrillation 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 41 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $179
$179 — —
Repatha
  • Amgen Inc. $144
$144 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $136
$136 205 —
EVENITY
  • Amgen Inc. $132
$132 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record